Asceneuron is a Swiss clinical-stage biotechnology company focused on developing orally bioavailable small molecule therapeutics for tauopathies, with primary focus on Progressive Supranuclear Palsy (PSP). The company's proprietary approach targets the microtubule-associated protein tau (MAPT) through a novel mechanism involving enhancement of antisense oligonucleotide (ASO) activity, enabling oral delivery of tau-targeting therapies that have traditionally required intrathecal administration.
Asceneuron's lead program, ASN51, represents a first-in-class oral tau-lowering approach for PSP that could significantly improve patient convenience and treatment accessibility compared to existing antibody and ASO approaches that require intravenous or intrathecal delivery.
Science and Technology
Novel Mechanism: MAPT-tau ASO Enhancers
Asceneuron's platform is based on the discovery that certain small molecules can enhance the activity of antisense oligonucleotides targeting the MAPT gene. This approach offers several advantages:
Oral bioavailability — Small molecules can cross the blood-brain barrier when delivered orally
Tau isoform specificity — Can be designed to selectively reduce 4R tau isoforms (predominant in PSP)
Complementary to direct ASOs — Could potentially be combined with direct MAPT ASOs for additive effect
Improved patient compliance — Oral pills vs. infusions/injections
Lead Program: ASN51
ASN51 is an orally bioavailable small molecule that enhances MAPT ASO activity in the brain. By modulating splicing factors that regulate tau isoform expression, ASN51 can shift the equilibrium toward reduced 4R tau production — the predominant pathological isoform in PSP.
PSP is classified as a 4R-tauopathy, meaning that the pathological form of tau in PSP brains is the 4-repeat (4R) isoform. Normal adult human brain has roughly equal amounts of 3R and 4R tau, but in PSP, 4R tau accumulates disproportionately. Asceneuron's approach: